Predictors of Prostate Cancer at Fusion Biopsy: The Role of Positive Family History, Hypertension, Diabetes, and Body Mass Index.
body mass index
diabetes
family history
fusion biopsy
hypertension
prostate cancer
risk factors
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
12 05 2023
12 05 2023
Historique:
received:
25
03
2023
revised:
09
05
2023
accepted:
10
05
2023
medline:
29
5
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
PSA density and an elevated PI-RADS score are among the strongest predictors of prostate cancer (PCa) in a fusion biopsy. Positive family history, hypertension, diabetes, and obesity have also been associated with the risk of developing PCa. We aim to identify predictors of the prostate cancer detection rate (CDR) in a series of patients undergoing a fusion biopsy. We retrospectively evaluated 736 consecutive patients who underwent an elastic fusion biopsy from 2020 to 2022. Targeted biopsies (2-4 cores per MRI target) were followed by systematic mapping (10-12 cores). Clinically significant PCa (csPCa) was defined as ISUP score ≥ 2. Uni- and multi-variable logistic regression analyses were performed to identify predictors of CDR among age, body mass index (BMI), hypertension, diabetes, positive family history, PSA, a positive digital rectal examination (DRE), PSA density ≥ 0.15, previous negative biopsy status, PI-RADS score, and size of MRI lesion. The median patients' age was 71 years, and median PSA was 6.6 ng/mL. A total of 20% of patients had a positive digital rectal examination. Suspicious lesions in mpMRI were scored as 3, 4, and 5 in 14.9%, 55.0%, and 17.5% of cases, respectively. The CDR was 63.2% for all cancers and 58.7% for csPCa. Only age (OR 1.04, In a series of patients selected for a fusion biopsy, positive family history, hypertension, diabetes, or BMI are not predictors of PCa detection. PSA-density and PI-RADS score are confirmed to be strong predictors of the CDR.
Sections du résumé
BACKGROUND
PSA density and an elevated PI-RADS score are among the strongest predictors of prostate cancer (PCa) in a fusion biopsy. Positive family history, hypertension, diabetes, and obesity have also been associated with the risk of developing PCa. We aim to identify predictors of the prostate cancer detection rate (CDR) in a series of patients undergoing a fusion biopsy.
METHODS
We retrospectively evaluated 736 consecutive patients who underwent an elastic fusion biopsy from 2020 to 2022. Targeted biopsies (2-4 cores per MRI target) were followed by systematic mapping (10-12 cores). Clinically significant PCa (csPCa) was defined as ISUP score ≥ 2. Uni- and multi-variable logistic regression analyses were performed to identify predictors of CDR among age, body mass index (BMI), hypertension, diabetes, positive family history, PSA, a positive digital rectal examination (DRE), PSA density ≥ 0.15, previous negative biopsy status, PI-RADS score, and size of MRI lesion.
RESULTS
The median patients' age was 71 years, and median PSA was 6.6 ng/mL. A total of 20% of patients had a positive digital rectal examination. Suspicious lesions in mpMRI were scored as 3, 4, and 5 in 14.9%, 55.0%, and 17.5% of cases, respectively. The CDR was 63.2% for all cancers and 58.7% for csPCa. Only age (OR 1.04,
CONCLUSIONS
In a series of patients selected for a fusion biopsy, positive family history, hypertension, diabetes, or BMI are not predictors of PCa detection. PSA-density and PI-RADS score are confirmed to be strong predictors of the CDR.
Identifiants
pubmed: 37232832
pii: curroncol30050374
doi: 10.3390/curroncol30050374
pmc: PMC10217714
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4957-4965Références
JAMA. 2016 Jan 5;315(1):68-76
pubmed: 26746459
Int J Cancer. 2015 Dec 15;137(12):2795-802
pubmed: 25557753
Can J Urol. 2008 Feb;15(1):3866-71
pubmed: 18304396
Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1638-44
pubmed: 12496055
J Urol. 2020 Jul;204(1):24-32
pubmed: 31967522
J Endocrinol Invest. 2013 Feb;36(2):132-9
pubmed: 23481613
Br J Cancer. 1991 Jun;63(6):963-6
pubmed: 2069852
World J Urol. 2012 Apr;30(2):143-8
pubmed: 22116601
Cancer Prev Res (Phila). 2011 Apr;4(4):486-501
pubmed: 21233290
Curr Opin Urol. 2017 Sep;27(5):415-421
pubmed: 28632505
Curr Urol Rep. 2021 Mar 22;22(4):27
pubmed: 33748877
Clin Chem. 2015 Dec;61(12):1446-52
pubmed: 26510957
Rev Diabet Stud. 2017 Summer-Fall;14(2-3):279-294
pubmed: 29145538
Eur Urol. 2015 Jan;67(1):64-70
pubmed: 24568896
Front Biosci. 2006 May 01;11:1388-413
pubmed: 16368524
Cancers (Basel). 2021 Aug 19;13(16):
pubmed: 34439328
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Eur Urol. 2016 Jan;69(1):41-9
pubmed: 26361169
Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2936-42
pubmed: 25261967
PLoS Genet. 2011 May;7(5):e1001387
pubmed: 21637779
Prostate. 2023 Feb;83(2):162-168
pubmed: 36259316
Int J Urol. 2018 Dec;25(12):990-997
pubmed: 30187529
BMC Public Health. 2015 Sep 18;15:913
pubmed: 26385727
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
Prostate. 2012 Feb 1;72(2):147-56
pubmed: 21538423
BJU Int. 2011 Mar;107(6):929-35
pubmed: 20880183
J Natl Cancer Inst. 1968 Jan;40(1):43-68
pubmed: 5635018
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):
pubmed: 29311132
Eur Urol. 2012 Jun;61(6):1079-92
pubmed: 22424666
Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):422-8
pubmed: 18159981
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Nat Rev Urol. 2017 Jan;14(1):26-37
pubmed: 27995937
Eur Urol. 2012 Oct;62(4):656-61
pubmed: 22386193
Asian Pac J Cancer Prev. 2014;15(23):10237-40
pubmed: 25556453